Viatris Inc VTRS
News
Viatris to Participate in Upcoming Investor Conferences
Viatris Reports Third-Quarter 2026 Financial Results
Viatris Announces Quarterly Dividend
Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.
Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026
Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year
Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome
